Nanostring Technologies 

$0.11
71
+$0.02+19.66% Thursday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.95
-0.78
-0.61
-0.44
Expected EPS
-0.53
Actual EPS
N/A

Financials

-125.37%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
127.26MRevenue
-159.54MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NSTG. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with NanoString's nCounter Analysis System and GeoMx Digital Spatial Profiler.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers long-read sequencing technologies that compete with NanoString's technologies in the genomic research market, especially in complex genetic analysis.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a wide range of products for genomic analysis, including next-generation sequencing (NGS) and PCR solutions, competing with NanoString's genomic analysis products.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen provides sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing with NanoString in the molecular diagnostics and research market.
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Bio-Rad Laboratories offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components, competing in the genomic and proteomic research space.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing with NanoString in the cancer research and diagnostics market, particularly in genomic profiling.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is involved in CRISPR gene editing, a technology that competes indirectly with NanoString by offering alternative methods for genomic research and therapeutic development.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine is another company working on CRISPR gene editing, competing indirectly with NanoString in the genomic research space by providing alternative genome editing technologies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics also focuses on CRISPR/Cas9 gene editing, offering indirect competition to NanoString in the field of genomic research and potential therapeutic applications.

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
Show more...
CEO
R. Bradley Gray
Employees
766
Country
US
ISIN
US63009R1095
WKN
000A1W1X2

Listings

0 Comments

Share your thoughts

FAQ

What is Nanostring Technologies stock price today?
The current price of NSTG is $0.11 USD — it has increased by +19.66% in the past 24 hours. Watch Nanostring Technologies stock price performance more closely on the chart.
What is Nanostring Technologies stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nanostring Technologies stocks are traded under the ticker NSTG.
What is Nanostring Technologies revenue for the last year?
Nanostring Technologies revenue for the last year amounts to 127.26M USD.
What is Nanostring Technologies net income for the last year?
NSTG net income for the last year is -159.54M USD.
How many employees does Nanostring Technologies have?
As of April 02, 2026, the company has 766 employees.
In which sector is Nanostring Technologies located?
Nanostring Technologies operates in the Manufacturing sector.
When did Nanostring Technologies complete a stock split?
Nanostring Technologies has not had any recent stock splits.
Where is Nanostring Technologies headquartered?
Nanostring Technologies is headquartered in Seattle, US.